6.97
0.85%
-0.06
Pre-market:
6.97
Overview
News
Price History
Option Chain
Why GRFS Down?
Discussions
Forecast
Stock Split
Dividend History
Grifols SA ADR stock is currently priced at $6.97, with a 24-hour trading volume of 407.32K.
It has seen a -0.85% decreased in the last 24 hours and a -4.39% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.12 pivot point. If it approaches the $6.92 support level, significant changes may occur.
Previous Close:
$7.03
Open:
$7.14
24h Volume:
407.32K
Market Cap:
$4.73B
Revenue:
$7.21B
Net Income/Loss:
$211.12M
P/E Ratio:
24.17
EPS:
0.2884
Net Cash Flow:
$709.16M
1W Performance:
-7.19%
1M Performance:
-4.39%
6M Performance:
-33.56%
1Y Performance:
-19.05%
Grifols SA ADR Stock (GRFS) Company Profile
Name
Grifols SA ADR
Sector
Industry
Phone
34 93 571 05 00
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan Sant Cugat del Vallès, Barcelona
Grifols SA ADR Stock (GRFS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-12-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-16-23 | Upgrade | Barclays | Underweight → Equal Weight |
Jan-18-23 | Upgrade | Jefferies | Hold → Buy |
Apr-08-22 | Initiated | Morgan Stanley | Equal-Weight |
Nov-05-21 | Downgrade | Deutsche Bank | Buy → Hold |
Oct-19-21 | Downgrade | Barclays | Overweight → Underweight |
Oct-06-21 | Upgrade | Citigroup | Neutral → Buy |
Jun-14-21 | Upgrade | Deutsche Bank | Hold → Buy |
Apr-20-21 | Initiated | Deutsche Bank | Hold |
Mar-23-21 | Upgrade | Credit Suisse | Neutral → Outperform |
Mar-11-21 | Upgrade | HSBC Securities | Hold → Buy |
Oct-01-20 | Upgrade | Citigroup | Sell → Neutral |
Jun-09-20 | Downgrade | Citigroup | Neutral → Sell |
Jun-09-20 | Upgrade | HSBC Securities | Reduce → Hold |
Mar-25-20 | Downgrade | Citigroup | Buy → Neutral |
Jun-27-19 | Upgrade | JP Morgan | Neutral → Overweight |
Feb-08-19 | Downgrade | Berenberg | Buy → Hold |
Oct-11-18 | Upgrade | Berenberg | Hold → Buy |
Jun-01-18 | Initiated | Barclays | Overweight |
Oct-31-17 | Initiated | Citigroup | Buy |
Jun-30-17 | Downgrade | Goldman | Buy → Neutral |
Apr-06-17 | Initiated | BofA/Merrill | Buy |
Jan-03-17 | Upgrade | JP Morgan | Neutral → Overweight |
Feb-09-16 | Upgrade | Berenberg | Hold → Buy |
Jan-04-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Dec-02-15 | Downgrade | HSBC Securities | Buy → Hold |
Nov-20-15 | Downgrade | Berenberg | Buy → Hold |
Apr-28-15 | Downgrade | Berenberg | Buy → Hold |
View All
Grifols SA ADR Stock (GRFS) Latest News
Grifols SA ADR (GRFS)'s Day in Review: Closing at 6.97, Down by -1.97 – DWinneX - The Dwinnex
The Dwinnex
Taking on analysts' expectations and winning: Grifols SA ADR (GRFS) – Sete News - SETE News
SETE News
Grifols SA ADR (NASDAQ: GRFS): An Enticing Stock To Watch – Stocks Register - Stocks Register
Stocks Register
What is Grifols SA ADR (GRFS) Stock Return on Shareholders' Capital? – Sete News - SETE News
SETE News
What is Grifols SA ADR (GRFS) Stock Return on Shareholders' Capital? – Sete News - SETE News
SETE News
Metric Analysis: Grifols SA ADR (GRFS)'s Key Ratios in the Limelight – DWinneX - The Dwinnex
The Dwinnex
Grifols SA ADR Stock (GRFS) Financials Data
Grifols SA ADR (GRFS) Revenue 2024
GRFS reported a revenue (TTM) of $7.21 billion for the quarter ending December 31, 2023, a +15.31% rise year-over-year.
Grifols SA ADR (GRFS) Net Income 2024
GRFS net income (TTM) was $211.12 million for the quarter ending December 31, 2023, a -54.37% decrease year-over-year.
Grifols SA ADR (GRFS) Cash Flow 2024
GRFS recorded a free cash flow (TTM) of $709.16 million for the quarter ending June 30, 2021.
Grifols SA ADR (GRFS) Earnings per Share 2024
GRFS earnings per share (TTM) was $0.3111 for the quarter ending December 31, 2023, a -54.12% decline year-over-year.
About Grifols SA ADR
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Cap:
|
Volume (24h):